UTHR · United Therapeutics Corp
Price
Snapshot
50 fields · last close| Market Cap | $22.87B |
| P/E | 17.44 |
| Float | 41.58M |
| Beta | 0.50 |
| Volatility | 12.5% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 76.8 |
| Price | 545.37 |
| Change | +2.30% |
| Prev Close | 533.12 |
| Open | 545.49 |
| Day Low | 530.18 |
| Day High | 551.76 |
| Avg Vol | 1 |
| Avg $ Vol | $455.4M |
| 52W High | 609.35 |
| 52W Low | 409.07 |
| 52W Pos | 68.1% |
| From High | −10.50% |
| From Low | +33.32% |
| Max DD 1Y | −20.87% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +4.25% |
| SMA 50 | +5.97% |
| SMA 200 | +3.49% |
| RSI (14) | 53.1 |
| Vol 30D | 46.5% |
| Vol 90D | 32.5% |
| 1Y Range | 409–609 |
| Daily bars | 536 |
| Perf Week | −2.92% |
| Perf Month | +7.21% |
| Perf Quarter | +0.71% |
| Perf Half Y | −9.39% |
| Perf Year | +23.35% |
| Perf YTD | +9.79% |
| Prev Day | +2.30% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 6.60 |
| Int Cover | 15.0× |
| FCF Margin | 32.7% |
| Rev Growth | +10.6% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 11 / 35 |
Clavix risk grade
regraded every trading dayUTHR grades B, 76.8 of 100. Steadiest on Sector Resilience (75), most exposed on News Sentiment (52, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 11 of 35 in Biotechnology by Clavix score.
How rough the ride is
| UTHR | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.50 | 0.51 |
| Volatilityannualized | 12.5% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −20.9% | — |
| Typical daily movemedian absolute daily change | 0.98% | — |
| Days beyond ±3%of the last 252 sessions | 15 (6%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| UTHR | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.50 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| UTHR | |
|---|---|
| 1 week | −2.9% |
| 1 month | +7.2% |
| Year to date | +9.8% |
| 1 year | +23.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| UTHR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 8 Sep |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 17 · 6 |
| Directionarticles whose tone is improving vs worsening | 17 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| UTHR | |
|---|---|
| Revenue growthyear over year | +10.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openUnited Therapeutics settled its long-running legal fight with Liquidia, ending patent, trade secret, and antitrust disputes over treprostinil therapies. The article also notes a 24.95% one-year shareholder return, a three-year return above 100%, and a 0.62% dip in the share price over one day.
United Therapeutics and Liquidia reached a global settlement that ends all outstanding patent and antitrust lawsuits over pulmonary hypertension (high blood pressure in the lungs) treatments and clarifies each company's commercial rights to competing drugs. As part of the deal, Liquidia will change how it supports and supplies certain rival products.
Liquidia agreed to pay United Therapeutics $380.7 million to settle six legal disputes between the two companies, while gaining the right to sell its drug Yutrepia to pulmonary arterial hypertension (PAH) patients but with a narrower approved use than it had sought.
Liquidia has settled six legal disputes with United Therapeutics for $380.7 million, gaining the right to sell its dry-powder inhaled treprostinil (Yutrepia) to patients with pulmonary arterial hypertension (PAH, a type of high blood pressure in the lungs) but accepting a narrower approved label for the drug.
The article reports that United Therapeutics and Liquidia settled their patent dispute after a court ruling wiped out nearly half of Liquidia's stock value in one day, and the settlement reportedly cost Liquidia nearly all of its cash. Liquidia's stock then jumped 42%. The provided body text is too short to identify specific terms of the settlement.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| INCY | Incyte Corp | B+ | $22.92B | 14.21 | 0.79 | Compare |
| INSM | Insmed Inc | C | $21.02B | — | 0.83 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| EXEL | Exelixis Inc | B+ | $15.42B | 17.92 | 0.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $14.05B | 16.85 | 0.39 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $13.83B | 33.44 | 0.93 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $13.79B | 19.55 | 0.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.